FINWIRES · TerminalLIVE
FINWIRES

Wells Fargo Initiates Definium Therapeutics at Overweight

By

Definium Therapeutics, Inc. (DFTX) has an average rating of buy and mean price target of $60, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles